Royalty Pharma plc (RPRX) Revenue History
Annual and quarterly revenue from 2017 to present
RPRX Revenue Over Time (2017–2025)
RPRX Revenue Growth History
6 of 8 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- +12.3%
- FY2019 revenue growth
- +1.1%
- FY2020 revenue growth
- +17.0%
- FY2021 revenue growth
- +7.9%
- FY2022 revenue growth
- -2.3%
- FY2023 revenue growth
- +5.2%
- FY2024 revenue growth
- -3.9%
- FY2025 revenue growth
- +5.1%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $631.0M | +11.0% |
| Q4 2025 | $622.0M | +4.8% |
| Q3 2025 | $609.3M | +7.9% |
| Q2 2025 | $578.7M | +7.7% |
| Q1 2025 | $568.2M | +0.0% |
| Q4 2024 | $593.6M | -0.4% |
| Q3 2024 | $564.7M | +5.3% |
| Q2 2024 | $537.3M | -0.2% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
RPRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RPRX Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 23, 2026, Royalty Pharma plc (RPRX) generated trailing twelve-month (TTM) revenue of $2.44 billion, reflecting strong growth of +11.0% year-over-year. The most recent quarter (Q1 2026) recorded $631.0 million in revenue, up 1.4% sequentially.
Historical Growth Trajectory
RPRX's 5-year compound annual growth rate (CAGR) stands at +2.3%, indicating moderate growth over time. The 3-year CAGR of +2.1% is in line with the 5-year average, suggesting consistent growth. Royalty Pharma plc's highest annual revenue of $2.38 billion was recorded in 2025, an all-time high.
Revenue by Segment
RPRX's revenue is primarily driven by Financial Royalty Assets (95%), and Royalty Income, Other (5%). With over half of revenue concentrated in Financial Royalty Assets, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including RCUS (+67.4% YoY), OR (+51.8% YoY), and WPM (+88.3% YoY) — RPRX has underperformed the peer group in revenue growth. Compare RPRX vs RCUS →
RPRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RPRXCurrent | $2.4B | +11.0% | +2.3% | 65.6% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 OR | $282M | +51.8% | +5.7% | 72.9% | |
 WPM | $2.4B | +88.3% | +16.5% | 68.8% | |
 RGLD | $1.0B | +72.1% | +10.8% | 64.5% | |
 FNV | $1.8B | +71.8% | +12.3% | 71.4% |
RPRX Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.38B | +5.1% | $2.38B | 100.0% | $1.56B | 65.6% |
| 2024 | $2.26B | -3.9% | $2.26B | 100.0% | $1.29B | 57.1% |
| 2023 | $2.35B | +5.2% | $2.35B | 100.0% | $1.49B | 63.4% |
| 2022 | $2.24B | -2.3% | $2.24B | 100.0% | $307.1M | 13.7% |
| 2021 | $2.29B | +7.9% | $2.29B | 100.0% | $1.43B | 62.5% |
| 2020 | $2.12B | +17.0% | $2.12B | 100.0% | $1.60B | 75.2% |
| 2019 | $1.81B | +1.1% | $1.81B | 100.0% | $2.62B | 144.6% |
| 2018 | $1.79B | +12.3% | $1.79B | 100.0% | $1.36B | 76.0% |
| 2017 | $1.60B | - | $1.60B | 100.0% | $939.7M | 58.8% |
Full Stock Analysis
Deep dive into RPRX consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RPRX — Frequently Asked Questions
Quick answers to the most common questions about buying RPRX stock.
Is RPRX's revenue growth accelerating or slowing?
RPRX revenue growth is holding steady at +11.0% year-over-year. TTM revenue is $2.4B. The current growth rate closely tracks the 5-year CAGR of +2.3%, signalling consistent execution.
What is RPRX's revenue history from 2017 to 2026?
Royalty Pharma plc (RPRX) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $2.4B, growing at +11.0% YoY. The 5-year CAGR is +2.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is RPRX's long-term revenue growth rate (CAGR)?
Royalty Pharma plc's 5-year revenue CAGR of +2.3% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +11.0% is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for RPRX.
Why does RPRX's quarterly revenue fluctuate?
RPRX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Royalty Pharma plc's revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is RPRX's revenue distributed by segment?
RPRX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does RPRX's revenue compare to industry peers?
Royalty Pharma plc (RPRX) with TTM revenue of $2.4B and +11.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.